This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Bacterial Infections  • Critical Care/ Intensive Care Medicine  • Adult Critical Care  • Randomized Controlled Trial  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

The EUPHAS Randomized Controlled Trial

Dinna N. Cruz, MD, MPH; Massimo Antonelli, MD; Roberto Fumagalli, MD; Francesca Foltran, MD; Nicola Brienza, MD, PhD; Abele Donati, MD; Vincenzo Malcangi, MD; Flavia Petrini, MD; Giada Volta, MD; Franco M. Bobbio Pallavicini, MD; Federica Rottoli, MD; Francesco Giunta, MD; Claudio Ronco, MD

JAMA. 2009;301(23):2445-2452.

Context  Polymyxin B fiber column is a medical device designed to reduce blood endotoxin levels in sepsis. Gram-negative–induced abdominal sepsis is likely associated with high circulating endotoxin. Reducing circulating endotoxin levels with polymyxin B hemoperfusion could potentially improve patient clinical outcomes.

Objective  To determine whether polymyxin B hemoperfusion added to conventional medical therapy improves clinical outcomes (mean arterial pressure [MAP], vasopressor requirement, oxygenation, organ dysfunction) and mortality compared with conventional therapy alone.

Design, Setting, and Patients  A prospective, multicenter, randomized controlled trial (Early Use of Polymyxin B Hemoperfusion in Abdominal Sepsis [EUPHAS]) conducted at 10 Italian tertiary care intensive care units between December 2004 and December 2007. Sixty-four patients were enrolled with severe sepsis or septic shock who underwent emergency surgery for intra-abdominal infection.

Intervention  Patients were randomized to either conventional therapy (n=30) or conventional therapy plus 2 sessions of polymyxin B hemoperfusion (n=34).

Main Outcome Measures  Primary outcome was change in MAP and vasopressor requirement, and secondary outcomes were PaO₂/FIO₂ (fraction of inspired oxygen) ratio, change in organ dysfunction measured using Sequential Organ Failure Assessment (SOFA) scores, and 28-day mortality.

Results  MAP increased (76 to 84 mm Hg; P = .001) and vasopressor requirement decreased (inotropic score, 29.9 to 6.8; P < .001) at 72 hours in the polymyxin B group but not in the conventional therapy group (MAP, 74 to 77 mm Hg; P = .37; inotropic score, 28.6 to 22.4; P = .14). The PaO₂/FIO₂ ratio increased slightly (235 to 264; P = .049) in the polymyxin B group but not in the conventional therapy group (217 to 228; P = .79). SOFA scores improved in the polymyxin B group but not in the conventional therapy group (change in SOFA, –3.4 vs –0.1; P < .001), and 28-day mortality was 32% (11/34 patients) in the polymyxin B group and 53% (16/30 patients) in the conventional therapy group (unadjusted hazard ratio [HR], 0.43; 95% confidence interval [CI], 0.20-0.94; adjusted HR, 0.36; 95% CI, 0.16-0.80).

Conclusion  In this preliminary study, polymyxin B hemoperfusion added to conventional therapy significantly improved hemodynamics and organ dysfunction and reduced 28-day mortality in a targeted population with severe sepsis and/or septic shock from intra-abdominal gram-negative infections.

Trial Registration  clinicaltrials.gov Identifier: NCT00629382

Author Affiliations: Department of Nephrology, Dialysis, and Transplantation, St Bortolo Hospital and International Renal Research Institute Vicenza, Vicenza (Drs Cruz and Ronco); Department of Anesthesiology and Intensive Care, Policlinico Gemelli, Catholic University of Sacred Heart, Rome (Dr Antonelli); Department of Anesthesiology and Intensive Care I, Milano Bicocca University, St Gerardo dei Tintori Hospital, Monza (Dr Fumagalli); Department of Surgery, University of Pisa, Pisa (Drs Foltran and Giunta); Department of Emergency and Organ Transplantation, Anesthesia and Intensive Care Unit, University of Bari, Bari (Drs Brienza and Malcangi); Department of Neuroscience, Anesthesia, and Intensive Care, Polytechnical University of Marche, Ancona (Dr Donati); Department of Anesthesia, Intensive Care, and Emergency, University of Chieti-Pescara, Chieti (Dr Petrini); Department of Anesthesiology and Intensive Care, Policlinico S. Orsola-Malpighi Hospital, Bologna (Dr Volta); Department of Intensive Care, S. Martino University Hospital, Genova (Dr Bobbio Pallavicini); and Department of Anesthesiology and Intensive Care, Riuniti Hospital, Bergamo (Dr Rottoli), Italy.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

International Differences in the Treatment of Sepsis: Are They Justified?
John A. Kellum and Shigehiko Uchino
JAMA. 2009;301(23):2496-2497.
EXTRACT | FULL TEXT  

Sepsis
Carolyn J. Hildreth, Cassio Lynm, and Richard M. Glass
JAMA. 2009;301(23):2516.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Polymyxin B Hemoperfusion Improves Outcomes in Abdominal Septic Shock
JWatch Emergency Med. 2009;2009:1-1.
FULL TEXT  

Get the Toxin Out?
JWatch Infect. Diseases 2009;2009:2-2.
FULL TEXT  

All you need to read in the other general journals
BMJ 2009;338:b2511-b2511.
FULL TEXT  

International Differences in the Treatment of Sepsis: Are They Justified?
Kellum and Uchino
JAMA 2009;301:2496-2497.
FULL TEXT